November NICE Guidance
The National Institute of Health and Clinical Excellence has published new guidance for the month of November.
Included in this month's guidance are Technology Appraisals covering Asthma (in children) - corticosteroids and Hypercholesterolaemia - ezetimibe.
The Quick Reference Guide for Asthma (in children) - corticosteroids recommends the least costly product should be used within licensed indications. Combination products containing corticosteroids and long acting beta agonists are recommended as an option after consideration of therapeutic need and the likelihood of treatment adherence.
The Quick Reference Guide for Hypercholesterolaemia - ezetimibe recommends ezetimibe as monotherapy in primary hypercholesterolaemia in patients who are contraindicated or intolerant to statins. It is also recommended for coadministration with a statin where patients fail to reach nationally defined cholesterol targets despite appropriate dose titration or where dose titration is limited by intolerance.
Action: Clinicians who treat children with asthma and patients with primary hypercholesterolaemia will find these technology appraisals useful.
« Hepatitis C awareness campaign | Catch It, Bin It, Kill It » |
Leave a Comment